Ipriflavone Explained

Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption,^[1] maintain bone density and to prevent osteoporosis in postmenopausal women.^[2] It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.

A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.^[3]

A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.^[4]

Ipriflavone has been described as a phytoestrogen.^[5] However, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women.^{[6] [7]} The drug prevents bone loss via mechanisms that are distinct from those of estrogens.

External links

• Ipriflavone at PDR Health

Notes and References

1. Civitelli R . In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics . Calcified Tissue International . 61 Suppl 1 . S12-4 . 1997 . 9263610 . 10.1007/s002239900378 . 21565791 .
2. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 651–.
3. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY . 6 . Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial . JAMA . 285 . 11 . 1482–8 . March 2001 . 11255425 . 10.1001/jama.285.11.1482 . Ipriflavone Multicenter European Fracture Study .
4. Sziklai I, Komora V, Ribári O . Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis . Acta Chirurgica Hungarica . 33 . 1–2 . 101–7 . 1992 . 1343452 .
5. Arjmandi BH, Birnbaum RS, Juma S, Barengolts E, Kukreja SC . The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms . Calcified Tissue International . 66 . 1 . 61–5 . January 2000 . 10602847 . 10.1007/s002230050012 . 31022310 .
6. Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi ML . Interactions between ipriflavone and the estrogen receptor . Calcified Tissue International . 56 . 2 . 160–5 . February 1995 . 7736326 . 10.1007/BF00296349 . 24212438 .
7. Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P . Lack of any estrogenic effect of ipriflavone in postmenopausal women . Journal of Endocrinological Investigation . 15 . 10 . 755–61 . November 1992 . 1491124 . 10.1007/BF03347647 . 32186052 .